3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole has been researched along with Alzheimer Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brioni, JD; Buckley, MJ; Decker, MW; Giardina, WJ; Kang, CH; Kim, DJ; Radek, RJ; Raszkiewicz, JL; Sullivan, JP; Wasicak, JT | 1 |
| Arneric, SP; Bannon, AW; Briggs, CA; Brioni, JD; Decker, MW; Donnelly-Roberts, D; Kyncl, J; Marsh, KC; Radek, RJ; Sullivan, JP | 1 |
| Nordberg, A; Warpman, U | 1 |
| Corwin, J; Lang, J; Lenox, R; Newhouse, PA; Piasecki, M; Potter, A | 1 |
1 trial(s) available for 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole and Alzheimer Disease
| Article | Year |
|---|---|
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydrocortisone; Isoxazoles; Learning; Male; Memory; Middle Aged; Nicotinic Agonists; Prolactin; Psychomotor Performance; Pyrrolidines | 1999 |
4 other study(ies) available for 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole and Alzheimer Disease
| Article | Year |
|---|---|
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
Topics: Alzheimer Disease; Animals; Anti-Anxiety Agents; Anticonvulsants; Avoidance Learning; Behavior, Animal; Body Temperature; Brain; Cerebrovascular Circulation; Cognition; Electroencephalography; Isoxazoles; Male; Mice; Mice, Inbred Strains; Motor Activity; Nicotine; Nociceptors; Pyrrolidines; Rats; Rats, Wistar; Receptors, Cholinergic; Seizures; Vomiting | 1994 |
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
Topics: Alzheimer Disease; Animals; Anti-Anxiety Agents; Avoidance Learning; Cognition; Dose-Response Relationship, Drug; Isoxazoles; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats | 1995 |
Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
Topics: Aged; Aged, 80 and over; Alkaloids; Alzheimer Disease; Animals; Anti-Anxiety Agents; Azocines; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured; Humans; Isoxazoles; Kinetics; Mice; Nicotine; Nicotinic Agonists; Pyridines; Pyrrolidines; Quinolizines; Receptors, Nicotinic; Temporal Lobe; Transfection | 1995 |
Health news. The sleeper syndrome.
Topics: Alzheimer Disease; Cacao; Humans; Hygiene; Isoxazoles; Margarine; Nicotine; Parkinson Disease; Pyrrolidines; Superoxides | 2001 |